治疗肺纤维化药物的评价与开发进展  

Progress in evaluation and development of drugs for treatment of pulmonary fibrosis

作　　者：邓龙[1,2,3] 邹晓青 姜德建[2] DENG Long;ZOU Xiao-qing;JIANG De-jian(College of Chemistry,Xiangtan University,Xiangtan 411105,China;Hunan Research Center for Safety Evaluation of Drugs,Hunan Key Laboratory of Pharmacodynamics and Safety Evaluation of New Drugs,Changsha 410331,China;High Tech Research Institute,Guangdong University of Petrochemical Technology,Maoming 525000,China)

机构地区：[1]湘潭大学化学学院,湘潭411105 [2]湖南省药物安全评价研究中心,新药药效与安全性评价湖南省重点实验室,长沙410331 [3]广东石油化工学院高新研究院,茂名525000

出　　处：《中国新药杂志》2021年第8期712-717,共6页Chinese Journal of New Drugs

摘　　要：肺纤维化是一大类肺疾病的终末期改变,是肺脏疾病致死的主要原因之一。本文综述了近年来肺纤维化发病机制、动物疾病模型、在研药物与药物作用新靶点的研究进展,旨在为治疗肺纤维化药物开发提供新思路。Pulmonary fibrosis(PF)is an advancing and fatal lung disease with increasing incidence and prevalence,which is one of the leading causes of death from lung diseases.This article summarizes the recent advances in disease pathogenesis,animal models,drugs under investigation and therapeutic targets,aiming to provide new ideas for developing drugs to treat pulmonary fibrosis.

关 键 词：肺纤维化 动物模型 药物开发 

分 类 号：R972.6[医药卫生—药品]